Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 16, 2022
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
Tue, November 15, 2022
[ Tue, Nov 15th 2022
] - WOPRAI
Jason Butler Maintained (VRDN) at Buy with Decreased Target to $46 on, Nov 15th, 2022
Jason Butler of JMP Securities, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Decreased Target from $47 to $46 on, Nov 15th, 2022.
Jason has made no other calls on VRDN in the last 4 months.
There are 2 other peers that have a rating on VRDN. Out of the 2 peers that are also analyzing VRDN, 0 agree with Jason's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Jason
- Michael Higgins of "Ladenburg Thalmann" Maintained at Strong Buy with Increased Target to $40 on, Tuesday, August 16th, 2022
- Mike Kratky of "SVB Leerink" Maintained at Buy with Increased Target to $40 on, Monday, August 15th, 2022
